Review Penggunaan Interval Docetaxel pada Kemoterapi
Interval Use of Docetaxel in Chemotherapy: a review
DOI:
https://doi.org/10.33084/jsm.v10i1.7207Keywords:
Dosetaksel, Kanker Payudara, JadwalAbstract
Modalitas terapi pada kanker salah satunya dengan kemoterapi. Dosetaksel merupakan salah satu obat sitostatika yang digunakan pada kemoterapi berbagai jenis kanker. Dosetaksel dapat digunakakan dalam regimen tunggal maupun kombinasi dan dapat diberikan dalam berbagai interval baik mingguan atau interval 3 minggu. Pada kemoterapi kanker payudara, docetaxel sebagai rejimen tunggal diberikan dengan dosis 60-100 mg/m2. Sedangkan pada interval mingguan dapat diberikan pada dosis dosis 35 mg/m2 selama 3 minggu diikuti dengan 1 minggu istirahat Dosis maksimal penggunaan dosetaksel di Indonesia adalan 100mg/m2. Tidak ada perbedaan secara signifikan terkait efikasi dari adanya perbedaan interval, namun dalam beberapa artikel disebutkan bahwa penggunaan dosetaksel mingguan lebih direkomendasikan pada pasien dengan riwayat toksisitas sebelumnya.
Downloads
References
Lee, D. W., Kang, I. H., & Ismail, F. 2020. Two-weekly docetaxel in treatment of advanced breast cancer: A preliminary study. The Medical Journal of Malaysia, 75(4), 338–341.
Martinez-Recio, S., Perez-Wert, J. P., Martinez-Fdez, S., Jimenez-Bou, D., Ruiz-Gutierrez, I., Peña, J., Pertejo, A., Espinosa, E., & Pinto, A. 2022. Comparison of 2-Weekly and 3-Weekly Dosing of Docetaxel in Metastatic Prostate Cancer. Clinical Genitourinary Cancer, 20(4), 363–370. https://doi.org/10.1016/j.clgc.2022.02.009
Piha-Paul, S. A., Thein, K. Z., De Souza, P., Kefford, R., Gangadhar, T., Smith, C., Schuster, S., Zamboni, W. C., Dees, C. E., & Markman, B. 2021. First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. Investigational New Drugs, 39(4), 1047–1056. https://doi.org/10.1007/s10637-021-01081-x
Rassy, E. E., Ghosn, M., Farhat, F., Bakouny, Z., Assi, T., Chahine, G., Nasr, F., Haddad, F. G., Karak, F. E., & Kattan, J. 2018. Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience. Breast Care, 13(2), 119–123. https://doi.org/10.1159/000481339
Sayin, M., & Celenkoglu, G. 2022. Comparison of Weekly Low Dose Docetaxel with the Standard Protocol in Hormone-resistant Metastatic Prostate Cancer. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP, 32(8), 1026–1032. https://doi.org/10.29271/jcpsp.2022.08.1026
van Eijk, M., Vermunt, M. A. C., van Werkhoven, E., Wilthagen, E. A., Huitema, A. D. R., & Beijnen, J. H. 2022. The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: A systematic review and meta-analysis of randomized controlled trials. BMC Cancer, 22(1), 104. https://doi.org/10.1186/s12885-022-09196-x
WHO. 2018. Cancer, last access 17 Juli 2023, available at https://www.who.int/health-topics/cancer#tab=tab_1
Yamashita, T., Shiota, M., Machidori, A., Kobayashi, S., Matsumoto, T., Monji, K., Kashiwagi, E., Takeuchi, A., Takahashi, R., Inokuchi, J., Shiga, K.-I., Yokomizo, A., & Eto, M. 2021. Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer. Cancer Investigation, 39(3), 251–256. https://doi.org/10.1080/07357907.2020.1871486
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Nunuk Wijayanti
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All rights reserved. This publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording.
